GNLX

GENELUX CorpCIK 1231457 ☆ Sign in to watch Congress trades

Open-mkt buys · 90d

—

0 trades · 0 insiders

Open-mkt sales · 90d

$293.4K

6 trades · 3 insiders

Net · 90d

$-293.4K

Insiders on file

AI insights for GNLX PRO

XXXX	$█.██M	██	+██%
XXXX	$█.██M	██	+██%
XXXX	$█.██M	██	+██%
XXXX	$█.██M	██	+██%
XXXX	$█.██M	██	+██%

AI insights for GNLX

Insider sentiment score with a plain-English explanation, conviction score on every buy, and how the stock performed 30 and 90 days after past insider buys.

Upgrade to Pro · $99/year Already Pro? Log in

Daily buy vs sell · 90 days

■ Open-market buys (P) ■ Open-market sales (S) · daily dollar value by transaction date

Insiders

Insider	Role	Trades	Bought	Sold	Last trade
Cappello Joseph	VP, Pharmaceutical Development	30	$0	$184.5K	2026-08-31
Zindrick Thomas	President and CEO	31	$0	$548.1K	2026-08-31
Yu Yong	VP, Clinical Trial Operations	54	$0	$3.30M	2026-08-31
Smither John W	Director	13	$0	$53.6K	2026-07-01
Pulisic Matthew	Chief Financial Officer	2	$0	$0	2026-06-16
Thomas John	Director	25	$0	$454.6K	2026-06-16
Mirabelli Mary	Director	12	$0	$0	2026-06-16
Groen Eric	General Counsel & Secretary	2	$0	$0	2026-06-16
Tyree James L	Director	16	$0	$131.9K	2026-06-16
Smalling Ralph	Head of Regulatory	25	$0	$43.3K	2026-06-03
Litten Jason	Chief Medical Officer	1	$0	$0	2026-01-02
Ryder Sean	General Counsel	15	$0	$332.5K	2025-05-12
Zak Lourie S.	Chief Financial Officer	8	$0	$4.9K	2024-12-18
Scigalla Paul	Chief Medical Officer	2	$0	$0	2024-10-18
Szalay Aladar	10% Owner	63	$0	$11.81M	2024-09-13
Jewett Caroline	Head of Quality	7	$0	$22.7K	2024-06-24
Samuelson Doug	Vice President, Finance	3	$0	$30.8K	2023-09-11
Woodward Gabe	Director	7	$0	$0	2023-02-17
Zhang Qian	Associate VP, Research	2	$1.3K	$0	2023-02-17

Trade history

Insider	Role	Code	Trade	Filed	Shares	Price	Value	Owned after
Yu Yong	Chief Scientific Officer	S Sale	2026-08-31	2026-09-02	9,683	$2.75	$26.6K	258,688	SEC↗
Zindrick Thomas	President and CEO	S Sale	2026-08-31	2026-09-02	34,463	$2.67	$92.0K	1,226,427	SEC↗
Cappello Joseph	Chief Technical Officer	S Sale	2026-08-31	2026-09-02	10,257	$2.74	$28.1K	318,480	SEC↗
Zindrick Thomas	President and CEO	S Sale	2026-08-31	2026-09-02	34,463	$2.67	$91.9K	1,226,427	SEC↗
Yu Yong	Chief Scientific Officer	S Sale	2026-08-31	2026-09-02	9,683	$2.75	$26.7K	258,688	SEC↗
Cappello Joseph	Chief Technical Officer	S Sale	2026-08-31	2026-09-02	10,257	$2.74	$28.1K	318,480	SEC↗
Zindrick Thomas	President and CEO	S Sale	2026-08-04	2026-08-04	3,023	$2.95	$8.9K	1,260,890	SEC↗
Cappello Joseph	Chief Technical Officer	S Sale	2026-08-04	2026-08-04	653	$2.95	$1.9K	328,737	SEC↗
Yu Yong	Chief Scientific Officer	S Sale	2026-08-04	2026-08-04	653	$2.94	$1.9K	268,371	SEC↗
Yu Yong	Chief Scientific Officer	S Sale	2026-08-04	2026-08-04	653	$2.94	$1.9K	268,371	SEC↗
Zindrick Thomas	President and CEO	S Sale	2026-08-04	2026-08-04	3,023	$2.95	$8.9K	1,260,890	SEC↗
Cappello Joseph	Chief Technical Officer	S Sale	2026-08-04	2026-08-04	653	$2.95	$1.9K	328,737	SEC↗
Smither John W	Director	S Sale	2026-07-01	2026-07-02	12,000	$2.91	$34.9K	91,403	SEC↗
Smither John W	Director	A Award deriv	2026-06-16	2026-06-18	31,566	—	$0	31,566	SEC↗
Mirabelli Mary	Director	A Award deriv	2026-06-16	2026-06-18	31,566	—	$0	31,566	SEC↗
Thomas John	Director	A Award deriv	2026-06-16	2026-06-18	31,566	—	$0	31,566	SEC↗
Tyree James L	Director	A Award deriv	2026-06-16	2026-06-18	31,566	—	$0	31,566	SEC↗
Smither John W	Director	A Award	2026-06-16	2026-06-18	28,409	—	$0	103,403	SEC↗
Yu Yong	Chief Scientific Officer	A Award	2026-06-16	2026-06-18	119,318	—	$0	269,024	SEC↗
Mirabelli Mary	Director	A Award	2026-06-16	2026-06-18	28,409	—	$0	102,693	SEC↗
Thomas John	Director	A Award	2026-06-16	2026-06-18	28,409	—	$0	501,193	SEC↗
Zindrick Thomas	President and CEO	A Award	2026-06-16	2026-06-18	730,601	—	$0	1,263,913	SEC↗
Tyree James L	Director	A Award	2026-06-16	2026-06-18	28,409	—	$0	96,483	SEC↗
Cappello Joseph	Chief Technical Officer	A Award	2026-06-16	2026-06-18	174,841	—	$0	329,390	SEC↗
Pulisic Matthew	Chief Financial Officer	A Award	2026-06-16	2026-06-18	278,906	—	$0	278,906	SEC↗
Groen Eric	General Counsel	A Award	2026-06-16	2026-06-18	233,957	—	$0	233,957	SEC↗
Smalling Ralph	Head of Regulatory	S Sale	2026-06-03	2026-06-04	192	$2.93	$563	67,611	SEC↗
Thomas John	Director	S Sale	2026-06-01	2026-06-02	10,000	$2.98	$29.8K	472,784	SEC↗
Smalling Ralph	Head of Regulatory	S Sale	2026-05-11	2026-05-12	270	$2.98	$805	67,803	SEC↗
Zindrick Thomas	President and CEO	S Sale	2026-05-11	2026-05-12	2,798	$2.94	$8.2K	532,051	SEC↗
Yu Yong	Chief Scientific Officer	S Sale	2026-05-11	2026-05-12	605	$2.97	$1.8K	149,706	SEC↗
Cappello Joseph	Chief Technical Officer	S Sale	2026-05-11	2026-05-12	605	$2.97	$1.8K	154,549	SEC↗
Smalling Ralph	Head of Regulatory	S Sale	2026-03-25	2026-03-26	240	$2.51	$602	68,073	SEC↗
Zindrick Thomas	President and CEO	S Sale	2026-03-24	2026-03-26	3,582	$2.42	$8.7K	534,849	SEC↗
Yu Yong	SVP, Clinical Development	S Sale	2026-03-24	2026-03-26	906	$2.42	$2.2K	144,938	SEC↗
Cappello Joseph	Chief Technical Officer	S Sale	2026-03-24	2026-03-26	906	$2.42	$2.2K	155,154	SEC↗
Smalling Ralph	Head of Regulatory	S Sale	2026-03-24	2026-03-26	345	$2.42	$835	68,313	SEC↗
Thomas John	Director	S Sale	2026-03-02	2026-03-03	10,000	$2.90	$29.0K	482,784	SEC↗
Litten Jason	Chief Medical Officer	A Award deriv	2026-01-02	2026-01-07	275,000	—	$0	275,000	SEC↗
Smalling Ralph	Head of Regulatory	S Sale	2025-12-05	2025-12-09	165	$4.69	$774	68,658	SEC↗
Thomas John	Director	S Sale	2025-12-01	2025-12-02	10,000	$5.00	$50.0K	492,784	SEC↗
Smalling Ralph	Head of Regulatory	S Sale	2025-11-17	2025-12-09	343	$5.37	$1.8K	68,823	SEC↗
Cappello Joseph	Chief Technical Officer	S Sale	2025-11-17	2025-12-11	973	$5.37	$5.2K	156,060	SEC↗
Yu Yong	SVP, Clinical Development	S Sale	2025-11-17	2025-12-11	973	$5.37	$5.2K	145,844	SEC↗
Zindrick Thomas	President and CEO	S Sale	2025-11-17	2025-12-11	4,509	$5.37	$24.2K	538,431	SEC↗
Smalling Ralph	Head of Regulatory	S Sale	2025-09-03	2025-12-09	580	$3.36	$1.9K	69,166	SEC↗
Cappello Joseph	Chief Technical Officer	A Award deriv	2025-09-01	2025-09-03	16,666	—	$0	16,666	SEC↗
Cappello Joseph	Chief Technical Officer	D To issuer deriv	2025-09-01	2025-09-03	16,666	—	$0	0	SEC↗
Cappello Joseph	Chief Technical Officer	D To issuer deriv	2025-09-01	2025-09-03	80,000	—	$0	0	SEC↗
Cappello Joseph	Chief Technical Officer	A Award deriv	2025-09-01	2025-09-03	80,000	—	$0	80,000	SEC↗
Cappello Joseph	Chief Technical Officer	D To issuer deriv	2025-09-01	2025-09-03	13,333	—	$0	0	SEC↗
Cappello Joseph	Chief Technical Officer	A Award deriv	2025-09-01	2025-09-03	13,333	—	$0	13,333	SEC↗
Cappello Joseph	Chief Technical Officer	D To issuer deriv	2025-09-01	2025-09-03	65,000	—	$0	0	SEC↗
Cappello Joseph	Chief Technical Officer	A Award deriv	2025-09-01	2025-09-03	65,000	—	$0	65,000	SEC↗
Smalling Ralph	Head of Regulatory	A Award deriv	2025-09-01	2025-09-03	8,333	—	$0	8,333	SEC↗
Smalling Ralph	Head of Regulatory	D To issuer deriv	2025-09-01	2025-09-03	8,333	—	$0	0	SEC↗
Yu Yong	SVP, Clinical Development	D To issuer deriv	2025-09-01	2025-09-03	207,652	—	$0	0	SEC↗
Yu Yong	SVP, Clinical Development	A Award deriv	2025-09-01	2025-09-03	207,652	—	$0	207,652	SEC↗
Yu Yong	SVP, Clinical Development	D To issuer deriv	2025-09-01	2025-09-03	65,000	—	$0	0	SEC↗
Yu Yong	SVP, Clinical Development	A Award deriv	2025-09-01	2025-09-03	65,000	—	$0	65,000	SEC↗
Zindrick Thomas	President and CEO	A Award deriv	2025-09-01	2025-09-03	925,000	—	$0	925,000	SEC↗
Zindrick Thomas	President and CEO	A Award deriv	2025-09-01	2025-09-03	250,000	—	$0	250,000	SEC↗
Zindrick Thomas	President and CEO	A Award deriv	2025-09-01	2025-09-03	157,372	—	$0	157,372	SEC↗
Zindrick Thomas	President and CEO	A Award deriv	2025-09-01	2025-09-03	23,568	—	$0	23,568	SEC↗
Zindrick Thomas	President and CEO	D To issuer deriv	2025-09-01	2025-09-03	250,000	—	$0	0	SEC↗
Zindrick Thomas	President and CEO	D To issuer deriv	2025-09-01	2025-09-03	925,000	—	$0	0	SEC↗
Zindrick Thomas	President and CEO	D To issuer deriv	2025-09-01	2025-09-03	23,568	—	$0	0	SEC↗
Zindrick Thomas	President and CEO	D To issuer deriv	2025-09-01	2025-09-03	157,372	—	$0	0	SEC↗
Smalling Ralph	Head of Regulatory	A Award	2025-09-01	2025-09-03	10,000	—	$0	70,990	SEC↗
Zindrick Thomas	President and CEO	A Award deriv	2025-08-27	2025-08-29	478,800	—	$0	478,800	SEC↗
Tyree James L	Director	A Award deriv	2025-08-27	2025-08-29	28,576	—	$0	28,576	SEC↗
Cappello Joseph	Chief Technical Officer	A Award deriv	2025-08-27	2025-08-29	142,500	—	$0	142,500	SEC↗
Yu Yong	SVP, Clinical Development	A Award deriv	2025-08-27	2025-08-29	134,520	—	$0	134,520	SEC↗
Mirabelli Mary	Director	A Award deriv	2025-08-27	2025-08-29	28,576	—	$0	28,576	SEC↗
Smither John W	Director	A Award deriv	2025-08-27	2025-08-29	28,576	—	$0	28,576	SEC↗
Smalling Ralph	Head of Regulatory	A Award deriv	2025-08-27	2025-08-29	34,770	—	$0	34,770	SEC↗
Thomas John	Director	A Award deriv	2025-08-27	2025-08-29	28,576	—	$0	28,576	SEC↗
Tyree James L	Director	A Award	2025-08-27	2025-08-29	22,283	—	$0	68,074	SEC↗
Smither John W	Director	A Award	2025-08-27	2025-08-29	22,283	—	$0	74,994	SEC↗
Cappello Joseph	Chief Technical Officer	A Award	2025-08-27	2025-08-29	107,500	—	$0	159,766	SEC↗
Smalling Ralph	Head of Regulatory	A Award	2025-08-27	2025-08-29	26,230	—	$0	60,990	SEC↗
Yu Yong	SVP, Clinical Development	A Award	2025-08-27	2025-08-29	101,480	—	$0	150,036	SEC↗
Mirabelli Mary	Director	A Award	2025-08-27	2025-08-29	22,283	—	$0	73,284	SEC↗
Thomas John	Director	A Award	2025-08-27	2025-08-29	22,283	—	$0	502,784	SEC↗
Zindrick Thomas	President and CEO	A Award	2025-08-27	2025-08-29	361,200	—	$0	554,161	SEC↗
Smalling Ralph	Head of Regulatory	S Sale	2025-08-21	2025-12-09	1,244	$3.36	$4.2K	69,746	SEC↗
Cappello Joseph	Chief Technical Officer	S Sale	2025-08-21	2025-12-11	1,463	$3.36	$4.9K	157,033	SEC↗
Cappello Joseph	Chief Technical Officer	S Sale	2025-08-21	2025-12-11	1,270	$3.33	$4.2K	158,496	SEC↗
Yu Yong	SVP, Clinical Development	S Sale	2025-08-21	2025-12-11	3,219	$3.36	$10.8K	146,817	SEC↗
Zindrick Thomas	President and CEO	S Sale	2025-08-21	2025-12-11	12,673	$3.33	$42.2K	542,940	SEC↗
Groen Eric	General Counsel & Secretary	A Award deriv	2025-07-01	2025-07-02	270,000	—	$0	270,000	SEC↗
Thomas John	Director	G Gift	2025-06-06	2025-06-24	25,000	—	$0	480,501	SEC↗
Smalling Ralph	Head of Regulatory	S Sale	2025-05-12	2025-05-13	1,259	$2.92	$3.7K	34,760	SEC↗
Cappello Joseph	VP, Pharmaceutical Developme	S Sale	2025-05-12	2025-05-13	4,737	$2.92	$13.8K	52,266	SEC↗
Yu Yong	VP, Clinical Trial Operation	S Sale	2025-05-12	2025-05-13	5,579	$2.92	$16.3K	47,640	SEC↗
Zindrick Thomas	President and CEO	S Sale	2025-05-12	2025-05-13	10,764	$2.92	$31.4K	191,447	SEC↗
Ryder Sean	General Counsel	S Sale	2025-05-12	2025-05-13	4,475	$2.92	$13.1K	47,621	SEC↗
Zindrick Thomas	President and CEO	A Award	2025-03-14	2025-04-17	30,339	—	$0	202,211	SEC↗
Ryder Sean	General Counsel	A Award	2025-03-14	2025-04-17	10,708	—	$0	52,096	SEC↗
Yu Yong	VP, Clinical Trial Operation	A Award	2025-03-14	2025-04-17	13,350	—	$0	53,219	SEC↗
Cappello Joseph	VP, Pharmaceutical Developme	A Award	2025-03-14	2025-04-17	13,350	—	$0	57,003	SEC↗
Smalling Ralph	Head of Regulatory	A Award	2025-03-14	2025-04-17	4,172	—	$0	36,019	SEC↗
Pulisic Matthew	Chief Financial Officer	A Award deriv	2025-01-31	2025-02-03	275,000	—	$0	275,000	SEC↗
Tyree James L	Director	S Sale	2024-12-30	2024-12-30	3,460	$2.46	$8.5K	45,791	SEC↗
Zindrick Thomas	President and CEO	A Award deriv	2024-12-18	2024-12-20	183,000	—	$0	183,000	SEC↗
Zak Lourie S.	Chief Financial Officer	A Award deriv	2024-12-18	2024-12-20	56,525	—	$0	56,525	SEC↗
Cappello Joseph	VP, Pharmaceutical Developme	A Award deriv	2024-12-18	2024-12-20	39,000	—	$0	39,000	SEC↗
Yu Yong	VP, Clinical Trial Operation	A Award deriv	2024-12-18	2024-12-20	39,000	—	$0	39,000	SEC↗
Ryder Sean	General Counsel	A Award deriv	2024-12-18	2024-12-20	30,000	—	$0	30,000	SEC↗
Smalling Ralph	Head of Regulatory	A Award deriv	2024-12-18	2024-12-20	21,100	—	$0	21,100	SEC↗
Zindrick Thomas	President and CEO	A Award	2024-12-18	2024-12-20	134,500	—	$0	171,872	SEC↗
Zak Lourie S.	Chief Financial Officer	A Award	2024-12-18	2024-12-20	41,650	—	$0	82,452	SEC↗
Cappello Joseph	VP, Pharmaceutical Developme	A Award	2024-12-18	2024-12-20	29,000	—	$0	43,653	SEC↗
Yu Yong	VP, Clinical Trial Operation	A Award	2024-12-18	2024-12-20	29,000	—	$0	39,869	SEC↗
Ryder Sean	General Counsel	A Award	2024-12-18	2024-12-20	22,000	—	$0	41,388	SEC↗
Smalling Ralph	Head of Regulatory	A Award	2024-12-18	2024-12-20	15,525	—	$0	31,847	SEC↗
Cappello Joseph	VP, Pharmaceutical Developme	S Sale	2024-12-16	2024-12-18	6,300	$2.34	$14.7K	14,653	SEC↗
Smalling Ralph	Head of Regulatory	S Sale	2024-12-16	2024-12-18	2,510	$2.34	$5.9K	16,322	SEC↗
Zak Lourie S.	Chief Financial Officer	S Sale	2024-12-16	2024-12-18	2,103	$2.34	$4.9K	40,802	SEC↗
Zindrick Thomas	President and CEO	S Sale	2024-12-16	2024-12-18	14,315	$2.34	$33.5K	37,372	SEC↗
Scigalla Paul	Chief Medical Officer	A Award deriv	2024-10-18	2024-10-21	16,666	—	$0	16,666	SEC↗
Scigalla Paul	Chief Medical Officer	A Award deriv	2024-10-18	2024-10-21	16,666	—	$0	16,666	SEC↗
Szalay Aladar	10% Owner	S Sale	2024-09-13	2024-09-13	33,080	$2.57	$85.0K	599,821	SEC↗
Szalay Aladar	10% Owner	S Sale	2024-09-12	2024-09-13	31,777	$2.73	$86.8K	632,901	SEC↗
Szalay Aladar	10% Owner	S Sale	2024-09-11	2024-09-11	31,376	$2.62	$82.2K	664,678	SEC↗
Tyree James L	Director	S Sale	2024-09-11	2024-09-12	1,730	$2.60	$4.5K	47,521	SEC↗
Szalay Aladar	10% Owner	S Sale	2024-09-10	2024-09-11	20,384	$2.51	$51.2K	696,054	SEC↗
Szalay Aladar	10% Owner	S Sale	2024-09-09	2024-09-11	23,383	$2.70	$63.1K	716,438	SEC↗
Szalay Aladar	10% Owner	S Sale	2024-09-03	2024-09-06	42,818	$2.09	$89.5K	739,821	SEC↗
Szalay Aladar	10% Owner	S Sale	2024-08-30	2024-08-30	142,589	$2.17	$309.4K	782,639	SEC↗
Szalay Aladar	10% Owner	S Sale	2024-08-29	2024-08-30	107,045	$1.98	$211.9K	925,228	SEC↗
Szalay Aladar	10% Owner	S Sale	2024-08-28	2024-08-30	15,918	$2.05	$32.6K	1,032,273	SEC↗
Szalay Aladar	10% Owner	S Sale	2024-08-27	2024-08-27	51,630	$2.11	$108.9K	1,048,191	SEC↗
Szalay Aladar	10% Owner	S Sale	2024-08-23	2024-08-27	40,000	$2.29	$91.6K	1,099,821	SEC↗
Tyree James L	Director	A Award deriv	2024-08-01	2024-12-31	50,469	—	$0	50,469	SEC↗
Smither John W	Director	A Award deriv	2024-08-01	2024-12-31	50,469	—	$0	50,469	SEC↗
Mirabelli Mary	Director	A Award deriv	2024-08-01	2024-12-31	50,469	—	$0	50,469	SEC↗
Thomas John	Director	A Award deriv	2024-08-01	2024-12-31	50,469	—	$0	50,469	SEC↗
Smither John W	Director	A Award deriv	2024-08-01	2024-08-05	50,469	—	$0	50,469	SEC↗
Thomas John	Director	A Award deriv	2024-08-01	2024-08-05	50,469	—	$0	50,469	SEC↗
Mirabelli Mary	Director	A Award deriv	2024-08-01	2024-08-05	50,469	—	$0	50,469	SEC↗
Tyree James L	Director	A Award deriv	2024-08-01	2024-08-05	50,469	—	$0	50,469	SEC↗
Smither John W	Director	A Award	2024-08-01	2024-08-05	39,541	—	$0	52,711	SEC↗
Thomas John	Director	A Award	2024-08-01	2024-08-05	39,541	—	$0	505,501	SEC↗
Mirabelli Mary	Director	A Award	2024-08-01	2024-08-05	39,541	—	$0	52,001	SEC↗
Tyree James L	Director	A Award	2024-08-01	2024-08-05	39,541	—	$0	49,251	SEC↗
Jewett Caroline	Head of Quality	S Sale	2024-06-24	2024-07-08	4,961	$2.12	$10.5K	16,174	SEC↗
Ryder Sean	General Counsel	S Sale	2024-06-24	2024-07-08	5,496	$2.12	$11.7K	19,388	SEC↗
Yu Yong	VP, Clinical Trial Operation	S Sale	2024-06-24	2024-07-08	6,849	$2.12	$14.5K	10,869	SEC↗
Zak Lourie S.	Chief Financial Officer	P Buy deriv	2024-05-29	2024-06-07	31,250	—	$0	31,250	SEC↗
Ryder Sean	General Counsel	P Buy deriv	2024-05-29	2024-06-07	10,000	—	$0	10,000	SEC↗
Smalling Ralph	Head of Regulatory	P Buy deriv	2024-05-29	2024-06-07	1,250	—	$0	1,250	SEC↗
Zindrick Thomas	President and CEO	P Buy deriv	2024-05-29	2024-06-07	200,000	—	$0	200,000	SEC↗
Yu Yong	VP, Clinical Trial Operation	P Buy deriv	2024-05-29	2024-06-07	2,500	—	$0	2,500	SEC↗
Mirabelli Mary	Director	P Buy deriv	2024-05-29	2024-06-07	8,000	—	$0	8,000	SEC↗
Thomas John	Director	P Buy deriv	2024-05-29	2024-06-07	2,500	—	$0	2,500	SEC↗
Smither John W	Director	P Buy deriv	2024-05-29	2024-06-07	6,250	—	$0	6,250	SEC↗
Tyree James L	Director	P Buy deriv	2024-05-29	2024-06-07	6,250	—	$0	6,250	SEC↗
Zak Lourie S.	Chief Financial Officer	P Buy	2024-05-29	2024-06-07	31,250	—	$0	31,250	SEC↗
Ryder Sean	General Counsel	P Buy	2024-05-29	2024-06-07	10,000	—	$0	10,572	SEC↗
Smalling Ralph	Head of Regulatory	P Buy	2024-05-29	2024-06-07	1,250	—	$0	13,315	SEC↗
Zindrick Thomas	President and CEO	P Buy	2024-05-29	2024-06-07	200,000	—	$0	200,000	SEC↗
Yu Yong	VP, Clinical Trial Operation	P Buy	2024-05-29	2024-06-07	2,500	—	$0	2,500	SEC↗
Mirabelli Mary	Director	P Buy	2024-05-29	2024-06-07	8,000	—	$0	12,460	SEC↗
Thomas John	Director	P Buy	2024-05-29	2024-06-07	2,500	—	$0	465,960	SEC↗
Smither John W	Director	P Buy	2024-05-29	2024-06-07	6,250	—	$0	13,170	SEC↗
Tyree James L	Director	P Buy	2024-05-29	2024-06-07	6,250	—	$0	9,710	SEC↗
Szalay Aladar	10% Owner	S Sale	2024-05-15	2024-05-15	17,094	$3.66	$62.6K	1,139,821	SEC↗
Szalay Aladar	10% Owner	S Sale	2024-05-14	2024-05-15	15,426	$3.58	$55.2K	1,156,915	SEC↗
Szalay Aladar	10% Owner	S Sale	2024-05-13	2024-05-15	3,446	$3.62	$12.5K	1,172,341	SEC↗
Szalay Aladar	10% Owner	S Sale	2024-05-08	2024-05-09	13,919	$3.82	$53.2K	1,175,787	SEC↗
Szalay Aladar	10% Owner	S Sale	2024-05-07	2024-05-09	6,025	$3.67	$22.1K	1,189,706	SEC↗
Szalay Aladar	10% Owner	S Sale	2024-05-01	2024-05-01	33,061	$3.30	$109.1K	1,195,731	SEC↗
Szalay Aladar	10% Owner	S Sale	2024-04-30	2024-05-01	20,535	$3.12	$64.1K	1,228,792	SEC↗
Szalay Aladar	10% Owner	S Sale	2024-04-29	2024-05-01	6,403	$3.25	$20.8K	1,249,327	SEC↗
Szalay Aladar	10% Owner	S Sale	2024-04-24	2024-04-24	8,064	$3.50	$28.2K	1,255,730	SEC↗
Szalay Aladar	10% Owner	S Sale	2024-04-23	2024-04-24	22,000	$3.49	$76.8K	1,263,794	SEC↗
Szalay Aladar	10% Owner	S Sale	2024-04-22	2024-04-24	14,331	$3.53	$50.6K	1,285,794	SEC↗
Szalay Aladar	10% Owner	S Sale	2024-04-17	2024-04-18	22,737	$3.71	$84.4K	1,300,125	SEC↗
Szalay Aladar	10% Owner	S Sale	2024-04-16	2024-04-18	48,683	$3.53	$171.9K	1,322,862	SEC↗
Jewett Caroline	Head of Quality	A Award	2024-03-14	2024-07-08	3,612	—	$0	25,890	SEC↗
Ryder Sean	General Counsel	A Award	2024-03-14	2024-07-08	9,270	—	$0	22,778	SEC↗
Yu Yong	VP, Clinical Trial Operation	A Award	2024-03-14	2024-07-08	11,557	—	$0	17,718	SEC↗
Cappello Joseph	VP, Pharmaceutical Developme	A Award	2024-03-14	2024-07-08	11,557	—	$0	20,953	SEC↗
Smalling Ralph	Head of Regulatory	A Award	2024-03-14	2024-07-08	2,107	—	$0	18,144	SEC↗
Zak Lourie S.	Chief Financial Officer	A Award	2024-03-14	2024-07-08	3,852	—	$0	38,428	SEC↗
Zindrick Thomas	President and CEO	A Award	2024-03-14	2024-07-08	26,264	—	$0	50,207	SEC↗
Jewett Caroline	Head of Quality	A Award	2024-02-19	2024-07-08	1,143	—	$0	22,278	SEC↗
Ryder Sean	General Counsel	A Award	2024-02-19	2024-07-08	2,936	—	$0	13,508	SEC↗
Yu Yong	VP, Clinical Trial Operation	A Award	2024-02-19	2024-07-08	3,661	—	$0	6,161	SEC↗
Cappello Joseph	VP, Pharmaceutical Developme	A Award	2024-02-19	2024-07-08	3,661	—	$0	9,396	SEC↗
Smalling Ralph	Head of Regulatory	A Award	2024-02-19	2024-07-08	616	—	$0	13,931	SEC↗
Zak Lourie S.	Chief Financial Officer	A Award	2024-02-19	2024-07-08	1,220	—	$0	32,470	SEC↗
Zindrick Thomas	President and CEO	A Award	2024-02-19	2024-07-08	8,320	—	$0	22,971	SEC↗
Yu Yong	VP, Clinical Trial Operation	S Sale	2023-12-15	2023-12-18	26,732	$12.94	$345.9K	5,803	SEC↗
Yu Yong	VP, Clinical Trial Operation	S Sale	2023-12-15	2023-12-18	5,803	$14.18	$82.3K	0	SEC↗
Thomas John	Director	S Sale	2023-12-13	2023-12-14	7,073	$13.23	$93.6K	465,387	SEC↗
Thomas John	Director	S Sale	2023-12-13	2023-12-14	1,927	$13.93	$26.8K	463,460	SEC↗
Tyree James L	Director	S Sale	2023-12-13	2023-12-14	5,653	$12.91	$73.0K	6,807	SEC↗
Tyree James L	Director	S Sale	2023-12-13	2023-12-14	3,347	$13.73	$46.0K	3,460	SEC↗
Yu Yong	VP, Clinical Trial Operation	S Sale	2023-12-07	2023-12-08	36,800	$11.85	$436.1K	32,535	SEC↗
Yu Yong	VP, Clinical Trial Operation	S Sale	2023-11-21	2023-11-22	18,665	$10.26	$191.5K	69,335	SEC↗
Yu Yong	VP, Clinical Trial Operation	S Sale	2023-11-20	2023-11-21	14,594	$11.26	$164.3K	88,000	SEC↗
Yu Yong	VP, Clinical Trial Operation	S Sale	2023-11-17	2023-11-21	3,541	$13.04	$46.2K	102,594	SEC↗
Szalay Aladar	10% Owner	S Sale	2023-10-25	2023-10-26	5,704	$19.40	$110.7K	1,371,545	SEC↗
Yu Yong	VP, Clinical Trial Operation	M Exercise deriv	2023-10-24	2023-10-25	5,200	—	$0	207,653	SEC↗
Yu Yong	VP, Clinical Trial Operation	M Exercise	2023-10-24	2023-10-25	5,200	$6.00	$31.2K	111,335	SEC↗
Yu Yong	VP, Clinical Trial Operation	S Sale	2023-10-24	2023-10-25	5,200	$19.11	$99.4K	106,135	SEC↗
Szalay Aladar	10% Owner	S Sale	2023-10-23	2023-10-25	49,987	$19.97	$998.2K	1,377,249	SEC↗
Thomas John	Director	S Sale	2023-10-16	2023-10-16	2,452	$20.50	$50.3K	473,341	SEC↗
Thomas John	Director	S Sale	2023-10-16	2023-10-16	881	$21.30	$18.8K	472,460	SEC↗
Yu Yong	VP, Clinical Trial Operation	M Exercise deriv	2023-10-10	2023-10-11	5,200	—	$0	212,853	SEC↗
Yu Yong	VP, Clinical Trial Operation	S Sale	2023-10-10	2023-10-11	4,800	$21.94	$105.3K	106,535	SEC↗
Yu Yong	VP, Clinical Trial Operation	S Sale	2023-10-10	2023-10-11	400	$22.91	$9.2K	106,135	SEC↗
Yu Yong	VP, Clinical Trial Operation	M Exercise	2023-10-10	2023-10-11	5,200	$6.00	$31.2K	111,335	SEC↗
Szalay Aladar	10% Owner	S Sale	2023-10-05	2023-10-10	13,266	$24.89	$330.2K	1,428,221	SEC↗
Szalay Aladar	10% Owner	S Sale	2023-10-05	2023-10-10	985	$25.47	$25.1K	1,427,236	SEC↗
Szalay Aladar	10% Owner	S Sale	2023-10-03	2023-10-04	75,690	$25.49	$1.93M	1,441,487	SEC↗
Jewett Caroline	Head of Quality	A Award deriv	2023-10-02	2023-10-04	22,000	—	$0	22,000	SEC↗
Szalay Aladar	10% Owner	S Sale	2023-09-28	2023-09-29	2,289	$24.12	$55.2K	1,517,177	SEC↗
Szalay Aladar	10% Owner	S Sale	2023-09-27	2023-09-29	11,257	$24.47	$275.5K	1,519,466	SEC↗
Yu Yong	VP, Clinical Trial Operation	M Exercise deriv	2023-09-26	2023-09-27	5,200	—	$0	218,053	SEC↗
Yu Yong	VP, Clinical Trial Operation	M Exercise	2023-09-26	2023-09-27	5,200	$6.00	$31.2K	111,335	SEC↗
Yu Yong	VP, Clinical Trial Operation	S Sale	2023-09-26	2023-09-27	1,883	$22.54	$42.4K	109,452	SEC↗
Yu Yong	VP, Clinical Trial Operation	S Sale	2023-09-26	2023-09-27	2,203	$24.46	$53.9K	106,135	SEC↗
Yu Yong	VP, Clinical Trial Operation	S Sale	2023-09-26	2023-09-27	1,114	$23.51	$26.2K	108,338	SEC↗
Szalay Aladar	10% Owner	S Sale	2023-09-26	2023-09-27	12,740	$24.03	$306.1K	1,540,323	SEC↗
Szalay Aladar	10% Owner	S Sale	2023-09-26	2023-09-27	7,465	$22.47	$167.7K	1,553,063	SEC↗
Szalay Aladar	10% Owner	S Sale	2023-09-26	2023-09-27	9,600	$24.51	$235.3K	1,530,723	SEC↗
Szalay Aladar	10% Owner	S Sale	2023-09-25	2023-09-27	1,100	$27.81	$30.6K	1,560,528	SEC↗
Szalay Aladar	10% Owner	S Sale	2023-09-25	2023-09-27	1,900	$26.60	$50.5K	1,561,628	SEC↗
Szalay Aladar	10% Owner	S Sale	2023-09-25	2023-09-27	5,511	$25.75	$141.9K	1,563,528	SEC↗
Szalay Aladar	10% Owner	S Sale	2023-09-25	2023-09-27	3,947	$24.82	$98.0K	1,569,039	SEC↗
Szalay Aladar	10% Owner	S Sale	2023-09-22	2023-09-25	4,621	$27.76	$128.3K	1,572,986	SEC↗
Szalay Aladar	10% Owner	S Sale	2023-09-22	2023-09-25	4,421	$26.88	$118.8K	1,577,607	SEC↗
Szalay Aladar	10% Owner	S Sale	2023-09-21	2023-09-25	2,871	$27.89	$80.1K	1,586,706	SEC↗
Szalay Aladar	10% Owner	S Sale	2023-09-21	2023-09-25	4,678	$28.82	$134.8K	1,582,028	SEC↗
Ryder Sean	General Counsel	M Exercise deriv	2023-09-20	2023-09-21	10,000	—	$0	140,000	SEC↗
Yu Yong	VP, Clinical Trial Operation	M Exercise deriv	2023-09-20	2023-09-21	6,000	—	$0	223,253	SEC↗
Ryder Sean	General Counsel	M Exercise	2023-09-20	2023-09-21	10,000	$6.00	$60.0K	10,572	SEC↗
Ryder Sean	General Counsel	S Sale	2023-09-20	2023-09-21	10,000	$30.00	$300.0K	572	SEC↗
Yu Yong	VP, Clinical Trial Operation	S Sale	2023-09-20	2023-09-21	6,000	$27.96	$167.8K	106,135	SEC↗
Yu Yong	VP, Clinical Trial Operation	M Exercise	2023-09-20	2023-09-21	6,000	$6.00	$36.0K	112,135	SEC↗
Szalay Aladar	10% Owner	S Sale	2023-09-19	2023-09-20	23,920	$26.21	$626.9K	8,247	SEC↗
Szalay Aladar	10% Owner	S Sale	2023-09-19	2023-09-20	8,247	$27.16	$224.0K	0	SEC↗
Thomas John	Director	S Sale	2023-09-18	2023-09-18	3,334	$24.99	$83.3K	475,793	SEC↗
Szalay Aladar	10% Owner	S Sale	2023-09-18	2023-09-20	27,365	$23.20	$634.9K	7,927	SEC↗
Szalay Aladar	10% Owner	S Sale	2023-09-18	2023-09-20	2,927	$24.17	$70.7K	5,000	SEC↗
Yu Yong	VP, Clinical Trial Operation	M Exercise deriv	2023-09-15	2023-09-18	10,400	—	$0	229,253	SEC↗
Thomas John	Director	S Sale	2023-09-15	2023-09-18	1,088	$22.38	$24.3K	479,127	SEC↗
Thomas John	Director	S Sale	2023-09-15	2023-09-18	2,245	$21.67	$48.6K	480,215	SEC↗
Yu Yong	VP, Clinical Trial Operation	S Sale	2023-09-15	2023-09-18	5,725	$21.56	$123.4K	110,810	SEC↗
Yu Yong	VP, Clinical Trial Operation	S Sale	2023-09-15	2023-09-18	4,675	$22.29	$104.2K	106,135	SEC↗
Yu Yong	VP, Clinical Trial Operation	M Exercise	2023-09-15	2023-09-18	10,400	$6.00	$62.4K	116,535	SEC↗
Szalay Aladar	10% Owner	S Sale	2023-09-14	2023-09-15	13,871	$22.31	$309.5K	35,292	SEC↗
Szalay Aladar	10% Owner	S Sale	2023-09-14	2023-09-15	11,405	$21.77	$248.3K	49,163	SEC↗
Smither John W	Director	S Sale	2023-09-13	2023-09-14	900	$20.78	$18.7K	6,920	SEC↗
Szalay Aladar	10% Owner	S Sale	2023-09-13	2023-09-15	3,315	$22.31	$74.0K	60,568	SEC↗
Szalay Aladar	10% Owner	S Sale	2023-09-13	2023-09-15	15,717	$21.26	$334.1K	63,883	SEC↗
Yu Yong	VP, Clinical Trial Operation	S Sale	2023-09-13	2023-09-15	29,800	$21.14	$630.0K	106,135	SEC↗
Szalay Aladar	10% Owner	S Sale	2023-09-12	2023-09-13	13,727	$22.51	$309.0K	79,600	SEC↗
Szalay Aladar	10% Owner	S Sale	2023-09-12	2023-09-13	6,538	$21.75	$142.2K	93,327	SEC↗
Zak Lourie S.	Chief Financial Officer	A Award deriv	2023-09-11	2023-09-12	150,000	—	$0	150,000	SEC↗
Jewett Caroline	Head of Quality	A Award deriv	2023-09-11	2023-09-12	88,000	—	$0	88,000	SEC↗
Smalling Ralph	Head of Regulatory	A Award deriv	2023-09-11	2023-09-12	54,000	—	$0	54,000	SEC↗
Cappello Joseph	VP, Pharmaceutical Developme	A Award deriv	2023-09-11	2023-09-12	65,000	—	$0	65,000	SEC↗
Yu Yong	VP, Clinical Trial Operation	A Award deriv	2023-09-11	2023-09-12	65,000	—	$0	65,000	SEC↗
Samuelson Doug	Vice President, Finance	A Award deriv	2023-09-11	2023-09-12	40,000	—	$0	40,000	SEC↗
Ryder Sean	General Counsel	A Award deriv	2023-09-11	2023-09-12	40,000	—	$0	40,000	SEC↗
Smither John W	Director	A Award deriv	2023-09-11	2023-09-13	8,447	—	$0	8,447	SEC↗
Thomas John	Director	A Award deriv	2023-09-11	2023-09-13	4,397	—	$0	4,397	SEC↗
Tyree James L	Director	A Award deriv	2023-09-11	2023-09-13	4,397	—	$0	4,397	SEC↗
Mirabelli Mary	Director	A Award deriv	2023-09-11	2023-09-13	4,397	—	$0	4,397	SEC↗
Zindrick Thomas	President and CEO	A Award deriv	2023-09-11	2023-09-15	250,000	—	$0	250,000	SEC↗
Jewett Caroline	Head of Quality	A Award	2023-09-11	2023-09-12	20,000	—	$0	21,135	SEC↗
Smalling Ralph	Head of Regulatory	A Award	2023-09-11	2023-09-12	10,000	—	$0	12,065	SEC↗
Szalay Aladar	10% Owner	S Sale	2023-09-11	2023-09-13	9,331	$21.39	$199.6K	122,885	SEC↗
Szalay Aladar	10% Owner	S Sale	2023-09-11	2023-09-13	23,020	$22.55	$519.1K	99,865	SEC↗
Smither John W	Director	A Award	2023-09-11	2023-09-13	6,920	—	$0	7,820	SEC↗
Thomas John	Director	A Award	2023-09-11	2023-09-13	3,460	—	$0	482,460	SEC↗
Tyree James L	Director	A Award	2023-09-11	2023-09-13	3,460	—	$0	12,460	SEC↗
Mirabelli Mary	Director	A Award	2023-09-11	2023-09-13	3,460	—	$0	4,460	SEC↗
Szalay Aladar	10% Owner	S Sale	2023-09-08	2023-09-11	8,523	$23.49	$200.2K	134,852	SEC↗
Szalay Aladar	10% Owner	S Sale	2023-09-08	2023-09-11	2,636	$24.19	$63.8K	132,216	SEC↗
Szalay Aladar	10% Owner	S Sale	2023-09-08	2023-09-11	13,672	$22.78	$311.4K	143,375	SEC↗
Szalay Aladar	10% Owner	S Sale	2023-09-07	2023-09-11	2,508	$25.34	$63.6K	157,047	SEC↗
Szalay Aladar	10% Owner	S Sale	2023-09-07	2023-09-11	9,938	$24.12	$239.7K	159,555	SEC↗
Yu Yong	VP, Clinical Trial Operation	S Sale	2023-08-30	2023-08-30	19,800	$24.70	$489.1K	135,935	SEC↗
Zindrick Thomas	President and CEO	S Sale	2023-08-18	2023-08-22	8,349	$23.73	$198.1K	14,651	SEC↗
Yu Yong	VP, Clinical Trial Operation	S Sale	2023-08-18	2023-08-22	3,265	$23.73	$77.5K	155,735	SEC↗
Cappello Joseph	VP, Pharmaceutical Developme	S Sale	2023-08-18	2023-08-22	3,265	$23.73	$77.5K	5,735	SEC↗
Ryder Sean	General Counsel	S Sale	2023-08-18	2023-08-22	328	$23.73	$7.8K	572	SEC↗
Samuelson Doug	Chief Financial Officer	S Sale	2023-08-18	2023-08-22	1,297	$23.73	$30.8K	2,303	SEC↗
Smalling Ralph	Head of Regulatory	S Sale	2023-08-18	2023-08-22	935	$23.73	$22.2K	2,065	SEC↗
Jewett Caroline	Head of Quality	S Sale	2023-08-18	2023-08-22	515	$23.73	$12.2K	1,135	SEC↗
Zindrick Thomas	President and CEO	A Award	2023-02-27	2023-05-02	23,000	—	$0	23,000	SEC↗
Cappello Joseph	VP, Pharmaceutical Developme	A Award	2023-02-17	2023-05-02	9,000	—	$0	9,000	SEC↗
Yu Tony	VP, Clinical Trial Operation	A Award	2023-02-17	2023-05-02	9,000	—	$0	159,000	SEC↗
Samuelson Doug	Chief Financial Officer	A Award	2023-02-17	2023-05-02	3,600	—	$0	3,600	SEC↗
Ryder Sean	General Counsel	A Award	2023-02-17	2023-05-02	900	—	$0	900	SEC↗